SCHEMBL23927170

SCHEMBL23927170

Fc1cccnc1C1=NCc2nnc(-c3cccnn3)n2-c2ccc(Cl)c(Cl)c21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 4/20 0.35
GABRA1 P14867 7/20 0.34
GABRA5 P31644 7/20 0.34
GABRA2 P47869 7/20 0.34
GABRA3 P34903 6/20 0.34
GABRB2 P47870 6/20 0.34
PTAFR P25105 5/20 0.33
OPRK1 P41145 2/20 0.32
GABRG2 P18507 1/20 0.32
HTR2A P28223 1/20 0.32
GABRB3 P28472 1/20 0.32
ADRA1A P35348 1/20 0.32
PDE4D Q08499 1/20 0.32
TSHR P16473 1/20 0.31
TNKS O95271 1/20 0.31
TNKS2 Q9H2K2 1/20 0.31
BRD4 O60885 1/20 0.31
LMNA P02545 1/20 0.31
HPGD P15428 1/20 0.31
CNR1 P21554 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30201991 1.00 P2RX7 (0.35) P2RX7GABRA1GABRA5GABRA2GABRA3
SCHEMBL25448187 0.92 GABRA1 (0.36) P2RX7GABRA1GABRA5GABRA2GABRA3
SCHEMBL30201913 0.91 GABRA1 (0.37) P2RX7GABRA1GABRA5GABRA2GABRA3
SCHEMBL23927175 0.91 GABRA1 (0.37) P2RX7GABRA1GABRA5GABRA2GABRA3
SCHEMBL30202034 0.89 P2RX7 (0.38) P2RX7GABRA1GABRA5GABRA2GABRA3
SCHEMBL23927178 0.89 P2RX7 (0.38) P2RX7GABRA1GABRA5GABRA2GABRA3
SCHEMBL30201869 0.89 P2RX7 (0.39) P2RX7GABRA1GABRA5GABRA2GABRA3
SCHEMBL23927198 0.89 P2RX7 (0.39) P2RX7GABRA1GABRA5GABRA2GABRA3
SCHEMBL23927164 0.88 PTAFR (0.43) P2RX7GABRA1GABRA5GABRA2GABRA3
SCHEMBL30202016 0.88 PTAFR (0.43) P2RX7GABRA1GABRA5GABRA2GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4139310-B1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM HOFFMANN LA ROCHE (CH) 2024-03-27 EP claimed
US-20230141603-A1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM HOFFMANN-LA ROCHE INC. (US) 2023-05-11 US claimed
CN-115667262-A Benzodiazepine derivatives as GABAA γ 1PAM 豪夫迈·罗氏有限公司 2023-01-31 CN claimed
EP-3901155-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM F. Hoffmann-La Roche AG (CH) 2021-10-27 EP claimed
EP-4139310-B1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM HOFFMANN LA ROCHE (CH) 2024-03-27 EP disclosed
US-20230141603-A1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM HOFFMANN-LA ROCHE INC. (US) 2023-05-11 US disclosed
US-20230141603-A1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM HOFFMANN-LA ROCHE INC. (US) 2023-05-11 US disclosed
US-20230141603-A1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM HOFFMANN-LA ROCHE INC. (US) 2023-05-11 US disclosed
CN-115667262-A Benzodiazepine derivatives as GABAA γ 1PAM 豪夫迈·罗氏有限公司 2023-01-31 CN disclosed
WO-2021213952-A1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM F. HOFFMANN-LA ROCHE AG (CH) 2021-10-28 WO disclosed
EP-3901155-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM F. Hoffmann-La Roche AG (CH) 2021-10-27 EP disclosed
EP-3901155-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM F. Hoffmann-La Roche AG (CH) 2021-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230141603-A1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM GABRA1, GABRB1, GABRB3 P2RX7 303/4885GABRA1 1/4885GABRA5 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.